Latest 杨贵妃传媒視頻 Health News Stories
杨贵妃传媒視頻 Health News' 'What the Health?': The Health of the Campaign
The 2024 presidential race is taking on a familiar tone 鈥 with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews 杨贵妃传媒視頻 Health News鈥 Lauren Sausser, who reported and wrote the latest 杨贵妃传媒視頻 Health News-Washington Post 鈥淏ill of the Month,鈥 about a teenage athlete whose needed surgery lacked a billing code.
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could鈥檝e brought down prices of some prescription drugs, but it was blocked by the courts.
California May Regulate and Restrict Pharmaceutical Brokers
California lawmakers are moving to rein in the pharmaceutical middlemen they say drive up costs and limit consumers鈥 choices. The bill sent to Gov. Gavin Newsom would require pharmacy benefit managers to be licensed in California and would ban some business practices. Newsom vetoed a previous effort three years ago.
With TV Drug Ads, What You See Is Not Necessarily What You Get
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
En los comerciales de medicamentos en TV, lo que ves no siempre es lo que es
Los anuncios de medicamentos han sido omnipresentes en la televisi贸n desde finales de la d茅cada de 1990 y se han extendido a internet y las redes sociales. Pocas naciones en el mundo los permiten
For Pharma, Trump vs. Harris Is a Showdown Between Two Industry Foes
Vice President Kamala Harris is seen as more aggressive than former President Donald Trump in taking on pharmaceutical companies, but Trump allies say he would also make lowering drug costs a top priority.
Para las farmac茅uticas, la pelea entre Trump y Harris es entre dos enemigos de la industria
Legisladores de ambos partidos atacan cada vez m谩s a la industria, por los precios de los medicamentos que la mayor铆a de los estadounidenses consideran irrazonables.
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark 鈥 Ozempic maker Novo Nordisk鈥檚 home 鈥 has limited coverage of the drug after cost overruns 鈥渆mptied all the money boxes in the entire public health system.鈥
Copycat Weight-Loss Drugs Are Major Players With Consumers
As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren鈥檛 getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though […]
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma鈥檚 Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
Qu茅 son los medicamentos compuestos que millones de personas usan para bajar de peso
La FDA permite e incluso fomenta que las farmacias de compuestos produzcan y vendan copias cuando un medicamento est谩 en escasez, como es el caso de las drogas para combatir el sobrepeso y la obesidad.
1st Biden-Trump Debate of 2024: What They Got Wrong, and Right
A debate marked by President Joe Biden鈥檚 faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
杨贵妃传媒視頻 Health News' 'What the Health?': SCOTUS Rejects Abortion Pill Challenge 鈥 For Now聽
The Supreme Court has dismissed a challenge to the FDA鈥檚 approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of 杨贵妃传媒視頻 Health News, and Emmarie Huetteman of 杨贵妃传媒視頻 Health News join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF鈥檚 new 鈥淗ealth Policy 101鈥 primer.
Weight-Loss Drugs Are So Popular They鈥檙e Headed for Medicare Negotiations
The steep prices 鈥 and popularity 鈥 of Ozempic and similar weight-loss and diabetes drugs could soon make them a priority for Medicare drug price negotiations. List prices for a month鈥檚 supply of the drugs range from $936 to $1,349, according to the Peterson-杨贵妃传媒視頻 Health System Tracker. The Inflation Reduction Act President Biden signed in […]
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
杨贵妃传媒視頻 Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here鈥檚 a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose 鈥 which earns it an additional $180,000 a year per patient.
杨贵妃传媒視頻 Health News' 'What the Health?': Abortion Access Changing Again in Florida and Arizona
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation鈥檚 third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of 杨贵妃传媒視頻 Health News join 杨贵妃传媒視頻 Health News鈥 Julie Rovner to discuss these stories and more. Plus, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.
This State Isn鈥檛 Waiting for Biden To Negotiate Drug Prices
As the federal government negotiates with drugmakers to lower the price of 10 expensive drugs for Medicare patients, impatient legislators in some states are trying to go even further. Leading the pack is Colorado, where a new Prescription Drug Affordability Review Board is set to recommend an 鈥渦pper payment limit鈥 for drugs it deems unaffordable. In late […]
